Kurowski, K.; Prozmann, S.N.; Cabrita Figueiredo, A.E.; Heyer, J.; Kind, F.; Schröder, K.-M.; Passlick, B.; Werner, M.; Bronsert, P.; Schmid, S.
The Ectonucleotidases CD39 and CD73 and the Purinergic Receptor P2X4 Serve as Prognostic Markers in Non-Small Cell Lung Cancer. Cancers 2025, 17, 1142.
https://doi.org/10.3390/cancers17071142
AMA Style
Kurowski K, Prozmann SN, Cabrita Figueiredo AE, Heyer J, Kind F, Schröder K-M, Passlick B, Werner M, Bronsert P, Schmid S.
The Ectonucleotidases CD39 and CD73 and the Purinergic Receptor P2X4 Serve as Prognostic Markers in Non-Small Cell Lung Cancer. Cancers. 2025; 17(7):1142.
https://doi.org/10.3390/cancers17071142
Chicago/Turabian Style
Kurowski, Konrad, Sophie Nicole Prozmann, António Eduardo Cabrita Figueiredo, Jannis Heyer, Felix Kind, Karl-Moritz Schröder, Bernward Passlick, Martin Werner, Peter Bronsert, and Severin Schmid.
2025. "The Ectonucleotidases CD39 and CD73 and the Purinergic Receptor P2X4 Serve as Prognostic Markers in Non-Small Cell Lung Cancer" Cancers 17, no. 7: 1142.
https://doi.org/10.3390/cancers17071142
APA Style
Kurowski, K., Prozmann, S. N., Cabrita Figueiredo, A. E., Heyer, J., Kind, F., Schröder, K.-M., Passlick, B., Werner, M., Bronsert, P., & Schmid, S.
(2025). The Ectonucleotidases CD39 and CD73 and the Purinergic Receptor P2X4 Serve as Prognostic Markers in Non-Small Cell Lung Cancer. Cancers, 17(7), 1142.
https://doi.org/10.3390/cancers17071142
